ArticleBritish journal of cancer2019
Intratumoural-infiltrating CD4 + and FOXP3 + T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer.
Article in British journal of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 81 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it, 123 citations in OpenAlex.
- Tumor characteristics impact prognosis in deficient mismatch repair/microsatellite instability-high localized colorectal cancer-a systematic review and meta-analysis.JNCI cancer spectrum · 2026Pooled it
- Association of tumor-infiltrating lymphocytes with survival depends on primary tumor sidedness in stage III colon cancers (NCCTG N0147) [Alliance].Annals of oncology : official journal of the European Society for Medical Oncology · 2022Trial
- Trial
- Foxp3+/CD4+ Cell Ratio in Primary Colorectal Cancer Predicts Opposite Prognoses Following Resection of Synchronous or Metachronous Liver Metastases.Cancer medicine · 2026Article
- Distribution and prognostic value of T-cells in primary colorectal cancer and adjacent non-tumor mucosa in stage IV versus stage I-III patients.International journal of cancer · 2026Article
- Increased Infiltration of CD4Cancer reports (Hoboken, N.J.) · 2026Observational
- Exploratory biomarker findings from regorafenib plus toripalimab in patients with refractory metastatic colorectal cancer (REGOTORI study).Gastroenterology report · 2026Article
- The Correlation ofCancers · 2026Article
- Evaluation of Proton Minibeam Radiotherapy on Antitumor Immune Responses in a Rat Model of Glioblastoma.Cancer immunology research · 2025Article
- Liver metastasis of colorectal cancer: Mechanism and clinical therapy (Review).Oncology reports · 2025Review
- Chemoprevention of Colorectal Cancer-With Emphasis on Low-Dose Aspirin and Anticoagulants.Pharmaceuticals (Basel, Switzerland) · 2025Review
- KCNC3 as a prognostic indicator and a predictive marker for immunotherapy in colorectal cancer.Journal of gastrointestinal oncology · 2025Article
- Transcriptome-Wide Analysis and Experimental Validation from FFPE Tissue Identifies Stage-Specific Gene Expression Profiles Differentiating Adenoma, Carcinoma In-Situ and Adenocarcinoma in Colorectal Cancer Progression.International journal of molecular sciences · 2025Article
- Prognostic assessment of T-cells in primary colorectal cancer and paired synchronous or metachronous liver metastasis.International journal of cancer · 2025Article
- The Impact of Nutritional Status and Tumor-Infiltrating Lymphocytes (CD4+ and CD8+) on Chemotherapy Response in Colorectal Cancer Patients.Cancer management and research · 2025Article
- The expression of CCL17 and potential prognostic value on tumor immunity in thyroid carcinoma based on bioinformatics analysis.Scientific reports · 2024Article
- Spatial distribution pattern of immune cells is associated with patient prognosis in colorectal cancer.Journal of translational medicine · 2024Article
- The tumor immune microenvironment and T-cell-related immunotherapies in colorectal cancer.Discover oncology · 2024Review
- Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer Predicted by CD4+, CD8+, and FOXP3+ Tumor-Infiltrating Lymphocytes.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Prognostic value of a modified‑immune scoring system in patients with pathological T4 colorectal cancer.Oncology letters · 2024Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
21 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCD3 + and CD8 + T-cell infiltration were reported as positive predictive markers of survival in colorectal cancer (CRC) patients. Here, we demonstrate the prognostic significance of CD4 + and FOXP3 + T-cell densities in CRC.
methodsWe quantified the intratumoural densities of CD3 + , CD8 + , CD4 + and FOXP3 + T cells by immunohistochemistry and digital pathology in 342 CRC patients who underwent curative resection. Microsatellite instability was also assessed in 322 specimens. Patient demographics, clinicopathological features and survival rates were analysed.
resultsHigh CD3 + , CD4 + and FOXP3 + T-cell densities were associated with improved relapse-free survival (RFS); high CD8 + , CD4 + and FOXP3 + T-cell densities were associated with improved disease-specific survival (DSS). Patients with low CD4 + and low FOXP3 + T-cell densities exhibited extremely poor prognoses. T stage, vascular/lymphatic invasion and CD4 + T-cell density were independent prognostic indicators for DSS. The distributions of CD4 + and FOXP3 + T-cell densities were not significantly different between the high microsatellite instability group and other groups, in contrast to those of CD3 + and CD8 + T-cell densities.
conclusionsIntratumoural CD4 + T-cell density and combined CD4 + and FOXP3 + T-cell densities were stronger prognostic indicators than other clinicopathological features. These results may facilitate the establishment of novel prognostic factors and therapeutic strategies for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.